2022
Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation
Guo X, Xu L, Velazquez H, Chen TM, Williams RM, Heller DA, Burtness B, Safirstein R, Desir GV. Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation. Journal Of The American Society Of Nephrology 2022, 33: 342-356. PMID: 34921111, PMCID: PMC8819981, DOI: 10.1681/asn.2021040439.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsAntineoplastic AgentsCell LineCisplatinCreatinineDisease Models, AnimalGene ExpressionGlomerular Filtration RateHepatitis A Virus Cellular Receptor 1HumansKidneyMiceMice, Inbred C57BLMice, KnockoutMonoamine OxidaseNanocapsulesPeptidesRenal Insufficiency, ChronicConceptsRenal proximal tubulesSingle-cell RNA sequencing analysisMesoscale nanoparticlesFirst doseCisplatin chemotherapyProximal tubulesAgonist peptideInduced Chronic Kidney DiseaseGenetic deletionNeck squamous cell carcinomaRNA sequencing analysisCisplatin-induced AKIKidney-targeted deliveryChronic kidney diseaseDevelopment of CKDSquamous cell carcinomaAdministration of cisplatinPlasma renalaseAdvanced headCell carcinomaInflammatory cytokinesKidney diseasePlasma creatinineSystemic administrationRegulated necrosis
2005
Kv1.3 potassium channel blockade as an approach to insulin resistance
Desir GV. Kv1.3 potassium channel blockade as an approach to insulin resistance. Expert Opinion On Therapeutic Targets 2005, 9: 571-579. PMID: 15948674, DOI: 10.1517/14728222.9.3.571.Peer-Reviewed Original ResearchConceptsInsulin resistanceInsulin sensitivityKv1.3 channel inhibitionPotassium channel blockadePeripheral insulin sensitivityPotential therapeutic targetDevastating metabolic diseaseType II diabetesVoltage-gated potassium channelsAbnormal glucoseDiabetes mellitusInsulin deficiencyDevelopment of drugsInflammatory cytokinesChannel blockadeGlucose metabolismTherapeutic targetCardinal featuresMetabolic diseasesChannel inhibitionII diabetesLipid metabolismHealthcare expendituresPotassium channelsPromising target